ORIC to Participate at Citi 13th Annual Biotech Investor Conference

Thursday, August 30, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

SAN FRANCISCO, Aug. 30, 2018 /PRNewswire/ -- ORIC Pharmaceuticals, a clinical-stage oncology company focused on discovery

and development of novel therapies against treatment-resistant cancers, announced today that it will be participating in Citi's 13th Annual Biotech Conference in Boston on September 5th
On Wednesday, September 5, 2018 at 11:15 am ET, Jacob Chacko, MD, Chief Executive Officer, will participate in a panel discussion entitled, "Emerging Innovators – An Introduction to Biotech Privates."

About ORIC Pharmaceuticals

ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD and Scott Lowe, PhD, who have records of discovering innovative treatments and targets in cancer.  The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing.  ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.

For more information, please contact:

Krys Corbett

650-388-5622

200857@email4pr.com

http://oricpharma.com/

Cision View original content:http://www.prnewswire.com/news-releases/oric-to-participate-at-citi-13th-annual-biotech-investor-conference-300704327.html

SOURCE Oric Pharmaceuticals



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store